Stonepine Capital Management, LLC 13F holdings, Q2 2026
Holdings as of June 30, 2026 · filings on SEC EDGAR · this is the latest filing on record
Stonepine Capital Management, LLC disclosed 72 US equity positions worth $131.4m in its Q2 2026 13F filing. The largest position was VSTM at 9.7% of the reported book, followed by EOLS and TENX. Against the Q1 2026 filing, it opened 10 new positions, added to 20 and reduced 16 among the top 50 holdings.
What did Stonepine Capital Management, LLC own in Q2 2026? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2026 |
|---|---|---|---|---|---|---|---|
| 1 | VSTM VERASTEM INC | Healthcare | 9.7% | $12.8m | 3,349,627 | 1% | added |
| 2 | EOLS EVOLUS INC | Healthcare | 8.4% | $11.0m | 1,590,162 | -10% | reduced |
| 3 | TENX TENAX THERAPEUTICS INC | 7.3% | $9.6m | 660,000 | -32% | reduced | |
| 4 | NKTR NEKTAR THERAPEUTICS | Healthcare | 6.4% | $8.4m | 120,654 | 42% | added |
| 5 | ADMA ADMA BIOLOGICS INC | Healthcare | 4.7% | $6.2m | 740,000 | 0% | held |
| 6 | CAMP CAMP4 THERAPEUTICS CORP | 4.6% | $6.1m | 1,389,622 | 0% | held | |
| 7 | ELOXX PHARMACEUTICALS INC | 4.2% | $5.5m | 397,160 | – | new | |
| 8 | KZIA KAZIA THERAPEUTICS LTD | 3.7% | $4.9m | 345,179 | 0% | held | |
| 9 | INDV INDIVIOR PHARMACEUTICALS INC | Healthcare | 3.1% | $4.1m | 100,000 | – | new |
| 10 | CRBP CORBUS PHARMACEUTICALS HLDGS | Healthcare | 3.0% | $4.0m | 425,000 | 11% | added |
| 11 | MSLE SATELLOS BIOSCIENCE INC | 2.8% | $3.7m | 491,624 | 392% | added | |
| 12 | ZVRA ZEVRA THERAPEUTICS INC | 2.8% | $3.7m | 258,701 | -46% | reduced | |
| 13 | ABEO ABEONA THERAPEUTICS INC | Healthcare | 2.6% | $3.4m | 557,284 | -25% | reduced |
| 14 | EDSA EDESA BIOTECH INC | 2.4% | $3.2m | 456,439 | 1421% | added | |
| 15 | CABA CABALETTA BIO INC | Healthcare | 2.2% | $2.9m | 917,100 | 1734% | added |
| 16 | ANTX AN2 THERAPEUTICS INC | 2.0% | $2.7m | 551,692 | -23% | reduced | |
| 17 | XLO XILIO THERAPEUTICS INC | 1.6% | $2.2m | 225,994 | 252% | added | |
| 18 | ACET ADICET BIO INC | 1.6% | $2.1m | 245,518 | 11% | added | |
| 19 | TELA TELA BIO INC | 1.5% | $2.0m | 2,662,427 | 2% | added | |
| 20 | AYTU AYTU BIOPHARMA INC | 1.5% | $2.0m | 912,921 | 15% | added | |
| 21 | CRIS CURIS INC | 1.3% | $1.7m | 3,312,185 | -11% | reduced | |
| 22 | SPRB SPRUCE BIOSCIENCES INC | 1.2% | $1.6m | 28,795 | – | new | |
| 23 | OKYO OKYO PHARMA LTD | 1.0% | $1.3m | 862,996 | 2% | added | |
| 24 | KTTA PASITHEA THERAPEUTICS CORP | 0.9% | $1.1m | 2,201,468 | 165% | added | |
| 25 | SOL-GEL TECHNOLOGIES LTD | 0.8% | $1.1m | 14,469 | -48% | reduced | |
| 26 | LUNG PULMONX CORP | Healthcare | 0.8% | $1.1m | 815,436 | 6% | added |
| 27 | XFOR X4 PHARMACEUTICALS INC | 0.8% | $1.1m | 224,989 | -33% | reduced | |
| 28 | INAB IN8BIO INC | 0.7% | $980.4k | 695,287 | 5% | added | |
| 29 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 0.7% | $973.5k | 50,000 | – | new |
| 30 | QUOIN PHARMACEUTICALS LTD | 0.7% | $965.5k | 199,486 | 273% | added | |
| 31 | MXCT MAXCYTE INC | Healthcare | 0.7% | $924.5k | 751,606 | -25% | reduced |
| 32 | PHAT PHATHOM PHARMACEUTICALS INC | Healthcare | 0.7% | $922.4k | 85,010 | 70% | added |
| 33 | AZITRA INC | 0.7% | $886.9k | 5,285,476 | – | new | |
| 34 | CNTB CONNECT BIOPHARMA HLDGS LTD | 0.7% | $866.9k | 364,254 | 18% | added | |
| 35 | HELP CYBIN INC | 0.7% | $854.5k | 129,280 | -4% | reduced | |
| 36 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 0.6% | $834.8k | 25,000 | – | new |
| 37 | IKT INHIBIKASE THERAPEUTICS INC | 0.6% | $804.2k | 396,179 | -59% | reduced | |
| 38 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 0.6% | $783.7k | 161,583 | -40% | reduced |
| 39 | CTMX CYTOMX THERAPEUTICS INC. | Healthcare | 0.6% | $768.8k | 205,000 | 2% | added |
| 40 | NVCT NUVECTIS PHARMA INC | 0.6% | $735.6k | 40,000 | – | new | |
| 41 | CBIO CRESCENT BIOPHARMA INC. | 0.5% | $720.0k | 40,000 | -53% | reduced | |
| 42 | PMVP PMV PHARMACEUTICALS INC | Healthcare | 0.5% | $718.4k | 536,086 | -24% | reduced |
| 43 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 0.5% | $713.8k | 7,500 | – | new |
| 44 | RADIOPHARM THERANOSTICS LTD | 0.5% | $670.5k | 51,000,000 | 0% | held | |
| 45 | OKUR ONKURE THERAPEUTICS INC | 0.5% | $595.9k | 130,684 | -1% | reduced | |
| 46 | NERVGEN PHARMA CORP | 0.4% | $559.7k | 271,678 | – | new | |
| 47 | CALC CALCIMEDICA INC | 0.4% | $544.9k | 622,432 | – | new | |
| 48 | ARVN ARVINAS INC | Healthcare | 0.4% | $498.6k | 60,000 | 118% | added |
| 49 | BIOA BIOAGE LABS INC | 0.4% | $490.2k | 20,000 | -60% | reduced | |
| 50 | IRD OPUS GENETICS INC | 0.3% | $414.0k | 100,718 | 47% | added |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.